Irafamdastat
Irafamdastat (BMS-986368) (Example 74) is a FAAH and MAGL inhibitor, with IC50s ≤ 100 nM (human FAAH) and 100 nM-1 μM (human MAGL) respectively. Irafamdastat has antiepileptic effect[1][2].
Product Specifications
CAS Number
2244136-58-9
Product Name Alternative
BMS-986368; CC-97489; ABX-1772
UNSPSC
12352005
Target
FAAH; MAGL
Related Pathways
Metabolic Enzyme/Protease; Neuronal Signaling
Field of Research
Neurological Disease
Purity
98.07
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC(C1=CC(OC(N2[C@@H](CN(CC2)CC3=CC(OC(F)(F)F)=CC=C3)C)=O)=CN=C1)=O
Molecular Formula
C20H21F3N4O4
Molecular Weight
438.40
References & Citations
[1]Cheryl A. Grice, et al. Dual magl and faah inhibitors. Patent. US20180256566A1|[2]Tim Depmeier, et al. Carbamates with ortho-Substituted O-Phenyl Groups as Dual Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: Inhibitory Potency, Hydrolytic Stability, and QSAR Studies. 2025. ACS Medicinal Chemistry Letters.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
